Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAKR.L Regulatory News (AKR)

  • There is currently no data for AKR

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Further Distribution Agreement - PIFA Heparin/PF4

12 Aug 2010 07:00

RNS Number : 9463Q
Akers Biosciences, Inc.
12 August 2010
 



Embargoed: 0700hrs, 12 August 2010

 

Akers Biosciences, Inc.

("ABI" or the "Company")

 

Major PIFA Heparin/PF4 Contract

 

Akers Biosciences, Inc. (AIM:AKR), a leading designer and manufacturer of rapid diagnostic screening and testing products, is pleased to announce that the Company's PIFA Heparin/PF4 Rapid Assay has been added to the HealthTrust Purchasing Group (HPG) laboratory distribution contract.

 

HealthTrust Purchasing Group (HPG) is one of the leading Group Purchasing Organizations, supporting nearly 1,400 not-for-profit and for-profit acute care hospitals, including Hospital Corporation of America (HCA). HCA owns and operates over 160 hospitals and approximately 105 freestanding surgery centers in 20 US States and the United Kingdom. Other HPG members include a number of premier operators of US-based, acute care hospitals including Community Health Systems, Health Management Associates and Lifepoint.

ABI's President and CEO Thomas A. Nicolette commented:

"We were thrilled to get confirmation of HPG's addition of the PIFA Heparin/PF4 Rapid Assay to its laboratory products contract. PIFA's inclusion was spurred by demand from its member hospitals and we have already shipped orders. We have always been impressed with HPG's commitment to quality patient care and expertise in assessing value-oriented clinical products. We are confident that HPG's member hospitals will continue to find PIFA's time- and cost-saving benefits helpful in the clinical assessment of Heparin-Induced Thrombocytopenia."

 

 

Enquiries:

 

Thomas A. Nicolette

President and CEO

Tel. +1 856 848 8698

Ben Simons

M: Communications

Tel. +44 (0)20 7920 2340

 

Emma Earl

Daniel Stewart & Co.

Tel. +44 (0)20 7776 6550

 

  

 

About Akers Biosciences, Inc.

 

Akers Biosciences develops, manufactures, and supplies rapid, point of care screening and testing products designed to bring healthcare information both rapidly and directly to the consumer or healthcare provider. The Company has advanced the science of diagnostics while responding to major shifts in healthcare through the development of several proprietary platform technologies. The company's state-of-the-art rapid diagnostic assays can be performed virtually anywhere in minutes when time is of the essence. ABI has aligned with major healthcare companies and high volume medical products distributors to maximize product offerings, and to be a major worldwide competitor in diagnostics. Additional information on the Company and it products can be found at www.akersbiosciences.com.

 

 

About HealthTrust

HealthTrust Purchasing Group is a healthcare group purchasing organization. Established in May 1999, HPG's membership has tripled since its inception and the company supports over 1,400 not-for-profit and for-profit acute care hospitals, including HCA, Health Management Associates, Community Health Systems and Lifepoint, as well as over 3,000 ambulatory surgery centers, alternate care sites and physician practices. Annual purchasing volume is more than $14 billion with double-digit annual percentage growth expected. For more information, visit www.healthtrustcorp.com.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
CNTBRGDISSBBGGB
Date   Source Headline
14th Jul 20177:00 amRNSNotice of AGM & Directorate Changes
3rd Jul 20172:53 pmRNSForm S-3 Registration Statement
9th Jun 20174:51 pmRNSIssue of Equity
16th May 20177:00 amRNS1st Quarter Results
12th May 20172:30 pmRNSNotice of Q1 Results
5th May 201710:53 amRNSIssue of Equity
24th Apr 20175:12 pmRNSIssue of Equity
11th Apr 20179:13 amRNSHolding(s) in Company
11th Apr 20177:00 amRNSFinal Results
10th Apr 20173:00 pmRNSNotice of Results
10th Apr 201712:00 pmRNSIssue of Equity
10th Apr 20177:00 amRNSHeparin PF4 Rapid Test in Puerto Rico
6th Apr 20175:39 pmRNSIssue of Equity
4th Apr 20174:18 pmRNSIssue of Equity
31st Mar 20177:00 amRNSIssue of Equity
30th Mar 20171:30 pmRNSDetailed Year-end Trading Update
29th Mar 20177:00 amRNSNotice of Results
28th Mar 201712:00 pmRNSInitial Order for Rapid Cholesterol Self-test
16th Feb 20177:00 amRNSUS Patent for Akers Wellness Tests Cartridge
1st Feb 20177:00 amRNSTrading Update
13th Jan 20177:00 amRNSIssue of Equity
10th Jan 20177:00 amRNSIssue of Equity
9th Jan 20177:00 amRNSSupplement to Form S-3 Registration Statement
19th Dec 20165:00 pmRNSResult of AGM
19th Dec 20167:00 amRNSAgreement with GNYHA for PIFA Heparin PF4 Test
1st Dec 201612:00 pmRNSUS Distribution Agreement: Cholesterol Self-test
28th Nov 20167:06 amRNSClinical Trial for BreathScan DKA Completed
17th Nov 20167:00 amRNSSupplement to Form S-3 Registration Statement
14th Nov 201612:00 pmRNSNotice of AGM
14th Nov 20167:00 amRNS3rd Quarter Results
10th Nov 20167:00 amRNSEuropean Patent Granted
9th Nov 20164:29 pmRNSNotice of Q3 Results
25th Oct 20167:00 amRNSFiling of Form S-3 Registration Statement
19th Aug 20167:00 amRNSSettlement of Dispute with ChubeWorkx
18th Aug 20167:00 amRNSResults of OxiChek Test Study
11th Aug 20167:00 amRNSHalf Yearly Results
9th Aug 20164:00 pmRNSNotice of H1 2016 Earnings
30th Jun 20167:00 amRNSClinical Trial for Rapid Chlamydia Test Completed
27th Jun 20167:00 amRNSDistribution Agreement for BreathScan OxiChekT
14th Jun 201612:00 pmRNSIssue of Equity & PDMR Shareholding
26th May 20165:10 pmRNSPDMR Shareholding
12th May 20167:00 amRNSFinancial Results for Q1 2016
10th May 201612:00 pmRNSNotice of Q1 Results
25th Apr 201612:00 pmRNSBoard Rearrangement
30th Mar 20167:00 amRNSFinal Results
23rd Mar 20167:00 amRNSUS Patent - Heparin/PF4 Antibody Detection
16th Mar 20167:00 amRNSNotice of Results
2nd Mar 20167:00 amRNS$2.5M Product Order
29th Feb 20167:00 amRNSSenior Commercial Team Appointments
6th Jan 20167:00 amRNSDirectors Dealing

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.